The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

President and CEO of the Myasthenia Gravis Foundation of America. “The daily burden of CIDP from both the symptoms of the disease and interruption to daily life creates profound unseen ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 ...

In October 2006, the original trustees of the foundation, Bill Gates, Melinda French Gates and Warren Buffett, created a two-entity structure. One entity, the Bill & Melinda Gates Foundation, ...